235 related articles for article (PubMed ID: 32447055)
1. The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a "real world" context: focus on temporal lobe epilepsy.
Pascarella A; Iannone LF; Di Gennaro G; D'Aniello A; Ferlazzo E; Gagliostro N; Ursini F; Bonanni P; Paciello N; Romigi A; Aguglia U; De Sarro G; Russo E; Gambardella A; Labate A
J Neurol Sci; 2020 Aug; 415():116903. PubMed ID: 32447055
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
[TBL] [Abstract][Full Text] [Related]
3. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
[TBL] [Abstract][Full Text] [Related]
5. Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy.
Moraes JS; Hepworth G; Ignatiadis S; Dharan A; Carne R; Seneviratne U; Cook MJ; D'Souza WJ
Epilepsy Behav; 2020 Mar; 104(Pt A):106883. PubMed ID: 32045874
[TBL] [Abstract][Full Text] [Related]
6. The real-world effectiveness and safety of perampanel in Europe: A scoping review.
Estévez-María JC; Garamendi-Ruiz I
Epilepsy Behav; 2022 Sep; 134():108777. PubMed ID: 35816832
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study.
Wang Q; Xu Y; Chen Y; Wu X; Ge Y; Zhu G
Epilepsy Behav; 2022 Nov; 136():108937. PubMed ID: 36215830
[TBL] [Abstract][Full Text] [Related]
8. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.
Lin KL; Lin JJ; Chou ML; Hung PC; Hsieh MY; Chou IJ; Lim SN; Wu T; Wang HS
Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806
[TBL] [Abstract][Full Text] [Related]
11. The impact of perampanel treatment on quality of life and psychiatric symptoms in patients with drug-resistant focal epilepsy: An observational study in Italy.
Deleo F; Quintas R; Turner K; Didato G; Zambrelli E; Pappalardo I; Chiesa V; Pastori C; de Curtis M; Canevini MP; Villani F
Epilepsy Behav; 2019 Oct; 99():106391. PubMed ID: 31371205
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study.
Zhang R; Qiao S; Fang X; Wang K; Shi Y; Du Q; Yang T; Liu X
Front Neurol; 2021; 12():731566. PubMed ID: 34526963
[No Abstract] [Full Text] [Related]
13. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment.
Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D
Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260
[TBL] [Abstract][Full Text] [Related]
14. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice.
Trinka E; Alsaadi T; Goji H; Maehara T; Takahashi S; Jacobs J; Renna R; Gil-López FJ; McMurray R; Sáinz-Fuertes R; Villanueva V
Epilepsia; 2023 Aug; 64(8):2094-2107. PubMed ID: 37114853
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.
Santamarina E; Bertol V; Garayoa V; García-Gomara MJ; Garamendi-Ruiz I; Giner P; Aranzábal I; Piera A; Arcos C; Esteve P; Marinas A; García-Escrivá A; Viloria-Alebesque A; Loro FA; de Tienda AP; Olivan JA; Bonet M; Dávila-González P; Sivera R; Molins A; Sansa G; Roche JC; Martínez AB; Monteagudo S; Casadevall T
Seizure; 2020 Dec; 83():48-56. PubMed ID: 33096456
[TBL] [Abstract][Full Text] [Related]
16. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis.
Omatsu H; Watanabe T; Kira R; Ishiba K; Patten A; Takase T; Ngo LY
Seizure; 2023 Aug; 110():109-116. PubMed ID: 37336055
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
[TBL] [Abstract][Full Text] [Related]
18. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy.
Maguire M; Ben-Menachem E; Patten A; Malhotra M; Ngo LY
Epilepsy Behav; 2022 Jan; 126():108483. PubMed ID: 34953337
[TBL] [Abstract][Full Text] [Related]
19. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
[No Abstract] [Full Text] [Related]
20. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
